McKesson (MCK) Set to Announce Earnings on Thursday

McKesson (NYSE:MCK) is set to issue its quarterly earnings data after the market closes on Thursday, May 6th. Analysts expect the company to announce earnings of $5.00 per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Monday, February 1st. The company reported $4.60 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.13 by $0.47. McKesson had a return on equity of 45.52% and a net margin of 0.95%. The firm had revenue of $62.60 billion for the quarter, compared to analyst estimates of $61.70 billion. During the same quarter in the prior year, the company posted $3.81 earnings per share. McKesson’s quarterly revenue was up 5.8% on a year-over-year basis. On average, analysts expect McKesson to post $16 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Shares of MCK stock opened at $192.12 on Tuesday. The business’s fifty day moving average price is $191.70 and its 200 day moving average price is $179.04. McKesson has a 1-year low of $125.65 and a 1-year high of $198.43. The firm has a market capitalization of $30.58 billion, a PE ratio of 14.62, a P/E/G ratio of 1.70 and a beta of 0.94. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.99 and a quick ratio of 0.56.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 1st. Investors of record on Tuesday, June 1st will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, May 31st. McKesson’s dividend payout ratio is presently 11.24%.

McKesson announced that its board has approved a share buyback program on Tuesday, February 2nd that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 6.9% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

A number of analysts have commented on the company. Cowen boosted their target price on McKesson from $210.00 to $224.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 2nd. TheStreet downgraded McKesson from a “b” rating to a “d” rating in a research report on Tuesday, February 2nd. Deutsche Bank Aktiengesellschaft boosted their target price on McKesson from $222.00 to $231.00 and gave the stock a “buy” rating in a research report on Wednesday, February 3rd. Credit Suisse Group boosted their target price on McKesson from $178.00 to $192.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 3rd. Finally, Morgan Stanley boosted their target price on McKesson from $219.00 to $226.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $193.31.

In other McKesson news, CEO Brian S. Tyler sold 5,510 shares of the stock in a transaction that occurred on Tuesday, February 16th. The stock was sold at an average price of $183.38, for a total transaction of $1,010,423.80. Following the transaction, the chief executive officer now owns 24,500 shares of the company’s stock, valued at approximately $4,492,810. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Brian S. Tyler sold 5,511 shares of the stock in a transaction that occurred on Thursday, April 15th. The stock was sold at an average price of $191.41, for a total value of $1,054,860.51. Following the transaction, the chief executive officer now directly owns 24,501 shares in the company, valued at approximately $4,689,736.41. The disclosure for this sale can be found here. Corporate insiders own 0.28% of the company’s stock.

McKesson Company Profile

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products.

Further Reading: Understanding the different types of bonds

Earnings History for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.

Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit